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Article abstract—To determine whether MRI can reveal more vascular lesions in patients clinically suspected of hav­
ing vascular parkinsonism, we compared 15 such patients with 15 patients who had idiopathic Parkinson’s disease and 
10 hypertensive controls. Patients with suspected vascular parkinsonism had significantly more subcortical lesions 
than those with Parkinson’s disease or hypertension. The cutoff point that best distinguished patients with suspected 
vascular parkinsonism from patients with Parkinson’s disease was a 0.6% level of lesioned hrain tissue volume. There 
were two types of vascular parkinsonism: one had an acute onset and lesions located in the subcortical gray nuclei 
(striatum, globus pallidus, thalamus); the other had an insidious onset and lesions diffusely distributed in the water­
shed areas.
NEUROLOGY 1995;45:2183-2188
Since Critchley popularized the concept of “arte- parkinsonism.7'10 Atypical parkinsonism (without
riosclerotic parkinsonism” in 1929,1 many authors tremor or levodopa response) occurs with subcoi'ti-
have challenged its existence,2*5 CT and MRI have cal white or gray matter lesions (SCLs)7'10 that car-
provided support for the concept of vascular relate with arteriosclerosis, demyelinat.on with
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loss of axons, and chronic infarcts on postmortem 
stu d ies.11“15 Clinically, vascular parkinsonism— 
“lower-lialf parkinsonism”9 or “lower-body parkin­
sonism.”10—is dom inated by “frontal gait disor­
der,”16 with characteristic shuffling, short steps, 
start-and-turn hesitation, variable base (narrow to 
wide), and moderate disequilibrium.
The multiple etiologies of frontal gait disorder16 
make diagnosis of vascular parkinsonism difficult. 
Moreover, infarction of the basal ganglia and deep 
white matter (or SCLs on MRI and CT) occurs in 
elderly people who do not have parkinsonism.2’4,17'21 
Since some authors2*3 were unable to detect vascu­
lar lesions in patients meeting clinical criteria for 
idiopathic Parkinson’s disease (PD),22 the existence 
of vascular parkinsonism was denied. Caine et al23 
and Rowe and Kahn24 emphasized the necessity of 
obtaining proper controls. Because of the hetero­
geneity in risk factors for SCLs among nondiseased 
elderly,17'20 care is needed in selecting a control 
group w ith full knowledge of the distribution of 
their individual risk factors. The best choice for 
controls are neurologically normal elderly persons 
with chronic hypertension, the main vascular risk 
factor for SCLs.17*20
The aim of our study was to investigate whether 
MRI can yield evidence for vascular lesions in sus­
pected vascular parkinsonism. Therefore, we at­
tempted to determine whether (1) patients with 
clinically suspected vascular parkinsonism (SVP) 
have more SCLs on MRI than patients meeting 
clinical criteria for idiopathic PD; (2) SVP patients 
have more SCLs than hypertensive controls with­
out parkinsonism or gait disorder; (3) SCLs in SVP 
patients with an acute onset are located differently 
from SCLs in SVP patients with an insidious onset; 
and (4) the severity of parkinsonian symptoms in 
SVP patients is related to the volume and location 
of SCLs.
M ethods. Patients and controls. Fifteen PD patients (10 
men and 5 women; mean age, 72 ± 8 years; mean dura­
tion of disease, 7 ± 7 years), 15 SVP patients (11 men 
and 4 women; mean age, 72 + 4 years; mean duration of 
disease, 3 ± 3 years), and 10 hypertensive controls were 
examined clinically and with MRI. All PD and SVP pa­
tients were selected consecutively from the departments 
of neurology and geriatrics in our hospital; this was done 
without knowledge of any previous MRI or CT findings 
or of whether there was a history of vascular risk factors. 
PD was diagnosed in accordance with accepted clinical 
criteria.22 SVP was diagnosed in patients 60 years or 
older who had parkinsonism (hypokinesia and rigidity) 
dominated by frontal gait disorder9,10’16,25 and who were 
not ruled out by the following exclusion criteria: resting 
tremor, neuroleptic therapy, brain trauma, supranuclear 
gaze palsy, retrocollis, disproportionate antecollis, cere­
bellar signs at onset, fixed dystonic posture of the arm, 
action- or stimulus-sensitive myoclonus of the arm, alien 
hand syndrome, polyneuropathy, respiratory stridor, and 
orthostatic hypotension (>30 mm Hg).6,22,26 Four of the 
SVP patients had an acute onset (SVPa); in the remain­
der of SVP patients the onset was insidious (SVPi). One 
SVPa patient showed a good response to levodopa and
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carbidopa for 3 years, whereas in the others the response 
to levodopa and carbidopa (up to Sinemet 25-250 three 
times daily) was absent or minimal. Some SVP patients 
had dysarthria, pyramidal signs,, or signs of frontal lobe 
release, such as grasp reflexes or pseudobulbar reflexes. 
Four SVP patients had a history of hypertension, four of 
diabetes mellitus, and nine of a transient ischemic attack 
or reversible ischemic neurologic deficit. Patients with 
other neurologic diseases or with cognitive impairment 
(Mini-Mental State Examination score <23)27 were ex­
cluded.
The 10 hypertensive patients (6 men and 4 women; 
mean age, 70 ± 2 years; mean duration of hypertension, 
18 ± 13 years) were selected consecutively from the out­
patient department of internal medicine. They had nei­
ther parkinsonism nor gait disorder and met the exclu­
sion criteria as described above. All patients gave in­
formed consent prior to the examination in accordance 
with institutional guidelines,
Procedures, All patients and controls were examined by 
one investigator (J.C.M.Z,), who assessed severity of arm 
and leg rigidity in accordance with the Unified Parkin­
son’s Disease Rating Scale,28 severity of hypokinesia using 
a pegboard test as described in a previous study,29 and 
gait velocity during free-speed walking by measuring the 
time needed to cover a distance of 10 meters. Blood pres­
sure was measured with a legally stamped sphygmo­
manometer (Erka-meter 300) after 5 minutes of supine 
rest. At the time of clinical examination, no patient had 
taken levodopa during the preceding 12 hours.
MRI examination was performed with a 1.5-tesla Mag- 
netom and a spin-echo sequence using proton-density and 
T2 weighting (TE = 20 and 80 msec; TR = 2,500 msec). 
Images through the whole brain were acquired in the 
transverse plane, parallel to the intercomrnissural line, 
with a slice thickness of 4 mm and a slice gap of 0.4 mm. 
Spatial resolution was 0.95 mm, corresponding to a 256 x 
256 matrix. All images had an identical field of view.
Two investigators (J.C.M.Z. and O.J.M.V.), blind to 
the identities of the imaged patients, interpreted the im­
ages for the volume and location of SCLs as evident from 
areas with increased signal intensity on both short- and 
long-TE images. Perivascular dilatations (isointense rel­
ative to CSF on short-TE images) and hyperintense rims 
around the tip of the frontal horn were not scored, be­
cause they are of nonischemic origin.30,31
SCL volume was determined with a stereologic esti­
mation using a point-counting method (Gundersen and 
Jensen32) and the Cavalieri theorem of systematic sam­
pling.33 This method uses systematic sampling of parallel 
sections with a known, fixed interval (in this study, 4.4 
mm—ie, MRI slice thickness plus slice gap) and estima­
tion of area using counting grids. It was applied to esti­
mate the volume of cerebral ventricles in hydrocephalic 
patients on brain CT and to estimate the volume of sev­
eral brain structures in Down’s syndrome on MRI.34,35 
We estimated the total area of all SCLs (ASCL) on all MRI 
slices by superimposing a systematic array of test points 
on each slice. Giving random positioning of the test array 
on each slice, the total number of test points (2P) that hit 
SCLs affords an unbiased estimator of AScl- The exact 
relationship is expressed as
Ascl = SP X a(p) [in mm2],
where a(p) is the areal equivalent of one test point. Total 
volume of SCL (VSCL) is given by the formula
Vs cl [m mm3] = ASCL [in mm2] X 4.4 [in mm].
i
The coefficient of error of the estimate of each individual 
SCL volume declines in direct proportion to the total 
number of MRI slices and to the total number of test 
points.32 In our study, a coefficient of error of less than 
5% was obtained, because the number of MRI slices hit­
ting SCLs was 10 or more and the number of test points 
was 50 or more.36 The systematic and random errors of 
the VgcL estimates of the two investigators (interobserver 
variability), and also those of one investigator at two 
points separated by a 4-week interval (intraobserver 
variability), are described elsewhere.36 They were all ap­
proximately 10%. This indicates a high reproducibility of 
the method, especially when compared with the recently 
developed semiquantitative rating scales in which the 
severity of SCLs is expressed as a sum score of points 
awarded to subjective criteria, such as focal, multifocal, 
and confluent lesions,17'21»37 or punctate, nodular, and 
patchy lesions,38 yielding Cohen’s kappa coefficient val­
ues of inter- and intraobserver agreement ranging from 
0.34 to 0.73.37 The SCL volume was finally expressed as a 
percentage of total brain tissue volume: (Vscl/VBrain tissue)
x 100%, whereas VBrain tissue was obtained by a method 
similar to that for VSCL.
SCLs were also scored with respect to location of (1) 
territories of the three main cerebral arteries (anterior, 
middle, and posterior); (2) territories of the three water­
shed areas (between the anterior and middle cerebral ar­
teries, the middle and posterior cerebral arteries, and the 
deep and superficial middle cerebral arteries); and (3) 
the subcortical gray nuclei (putamen, caudate nucleus, 
globus pallidus, thalamus, and substantia nigra),
Statistics. To compare the SCL volume in the two SVP 
groups, PD patients, and hypertensive controls, the 
Mann-Whitney test with Bonferroni adjustment for mul­
tiple comparisons was used. To determine whether SVPa 
and SVPi patients could also be differentiated from one 
another by the presence of SCLs in the gray nuclei, 
Fisher’s exact test (two-tailed) was used. Finally, the 
severity of the parkinsonian symptoms of the SVP pa­
tients and their relation to the volume and location of 
SCLs were examined with Spearman’s rank correlation. 
For the unilateral tests (arm and leg rigidity, pegboard), 
the more severely affected side of the body was corre­
lated with the total SCL volume. In all test procedures, p  
values <0.05 were considered significant.
Results, SVP patients did not differ significantly 
from PD patients or hypertensive controls in age, 
systolic blood pressure, or diastolic blood pressure 
(table 1). The SVP group scored significantly lower 
than PD patients in rigidity in the upper and lower 
extremities (table 1). Pegboard score and walking 
velocity were not appreciably different between the 
two patient groups. SVP patients had a signifi­
cantly higher pegboard score and a significantly 
lower walking velocity than controls (table 1). The 
four SVPa patients were not crucially different 
from the 11 SVPi patients in age, systolic blood 
pressure, diastolic blood pressure, pegboard test, 
arm and leg rigidity, or walking velocity (data not 
shown). Current blood pressure did not differ sig­
nificantly by one-way ANOVA between the SVPi 
group and the controls ([152 ± 16]/[88 ± 11] mm Hg 
versus [166 ± 21]/[91 ± 8] mm Hg).
Figure 1 shows MRI studies of an SVPa and an 
SVPi patient. SVPi patients had markedly more
Table 1. P atient ch aracteristics
SVP (n = 15) P D  (n = 15) C o n tro ls  (n = 10)
(m ean  ± SD) (m e a n  ± SD) (m ean  ± SD)
Age (yr) 72 ± 4 72 ± 8 70 ± 2
Systolic BP 154 ± 18 145 ± 15 166 ± 21
(mm Hg)
Diastolic BP 91 ± 11 89 ± 15 91 ± 8
(mm Hg)
Pegboard test 10.8 ± 6 .1 10.6 ±6.1 5.7 ± 0.8f
(sec)
Arm rigidity 1.0 ± 0,8 2.0 ± 0.6f ---------
(UPDRS)
Leg rigidity 1.2 ± 0.9 1.9 ± 0.6* ---------
(UPDRS)
Velocity of 60 ± 2 6 59 ±29 117 ± 24t
walking
(cm/sec)
SVP Suspected vascular parkinsonism.
PD Parkinson’s disease.
BP Blood pressure.
UPDRS Unified Parkinson’s Disease Rating Scale.
* p  < 0.05; t  p < 0.01 (£ test): PD patients and controls com­
pared with SVP group.
1__________________________________________________________________________________________________________________________________________________________________________________________
SCLs than did patients with PD (p < 0.01; Mann- 
Whitney test) or hypertension (p < 0.05) (figure 2). 
SVPa patients had significantly more SCLs than  
did PD patients (p < 0.05), but not more than hy­
pertensive controls (figure 2). The SCL volume was 
not significantly different between the two SVP 
groups. A cutoff point for SCL volume of 0.6% of 
brain tissue volume resulted in the best discrimi­
nation between the PD and SVP groups (figure 2). 
Three hypertensive controls had an SCL volume 
>0.6% (table 2).
All four SVPa patients had SCLs in the gray nu­
clei, but only two of the 11 SVPi patients did (p = 
0.02; Fisher’s exact test, two-tailed) (table 2). None 
of the PD patients or controls had gray nuclei SCLs 
(table 2). SCLs in the gray nuclei were located in 
the putamen or thalamus alone or in one of those 
two nuclei along with the globus pallidus or cau­
date nucleus.
The severity of clinical symptoms (gait velocity, 
arm and leg rigidity, pegboard score) was signifi­
cantly correlated with neither the total SCL vol­
ume in the SVP patients nor the location of SCLs 
as seen from the subscores of the blood-supplying 
territories of the three main cerebral arteries, the 
three watershed areas between these three arter­
ies, and the subcortical gray nuclei (Spearman’s 
rank correlation). The SCLs were diffusely d is­
tributed, mainly in the three watershed areas, with 
only a small variation betw een the four patient 
groups. Of the total SCL load, 0 to 3% was located 
in the territories of the three main cerebral arter­
ies; 40 to 50% in the watershed area of the ante­
rior/middle cerebral arteries; 15 to 20% in the wa­
tershed area of the deep and superficial middle 
cerebral arteries; 30 to 40% in the watershed area 
of the middle/posterior cerebral arteries; and 0 to 
14% in the subcortical gray nuclei.
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tween SCLs and parkinsonism in our patients with 
SVP. The difference in SCL volume between the 
SVP and control patients was influenced neither by 
hypertension history nor by current blood pressure. 
Only four of 15 SVP patients had a history of hy­
pertension. Neither the current systolic nor the di­
astolic blood pressure differed between the two 
groups. Three of 10 hypertensive controls had an 
SCL volume >0.6% of brain tissue, indicating an 
overlap between the SVP patients and the controls. 
These results parallel the findings of Fazekas18 and 
Horikoshi et al,19 who reported frequencies of 10 to 
30% of partially or widely confluent lesions in 
asymptomatic elderly with vascular risk factors. 
Older persons without vascular risk factors may 
not serve as a control group, because of the proba­
bility of their having a lower SCL volume than our 
SVP patients who were not selected because of ab­
sence of vascular risk factors. PD patients are also 
not an optimal control group. They might have 
fewer vascular risk factors than most healthy indi­
viduals40’41; PD patients have a lower frequency of 
tobacco use,40>41 a known risk factor for athero­
sclerotic vascular disease.42
In both SVP groups, SCLs were diffusely located, 
mainly in the watershed areas, in agreement with 
reports by others.9,10’39 Furthermore, all four SVPa 
patients had SCLs in the gray nuclei, also in agree­
ment with other reports.7’8,39 In the four SVPa pa­
tients, subcortical gray nuclei lesions were located 
in the putamen or thalamus alone or in one of 
these two nuclei along with the globus pallidus or 
caudate nucleus. There were no SCLs in the sub­
stantia nigra. The differentiation of vascular 
parkinsonism into two types on the basis of stage of 
onset and location of SCLs has not been examined 
previously. There probably are more types of vascu­
lar parkinsonism in which other locations are in­
volved, such as types resem bling progressive 
supranuclear palsy.43,44
In patients with dementia11,45*46 or in whom men­
tal impairment was not excluded,47 the presence of 
gait impairment was associated with SCLs. We did 
not find a significant correlation between the sever­
ity of symptoms in the SVP patients and the vol­
ume or location of SCLs, probably because of the 
rather low SCL volume in our slightly affected SVP 
patients.
Thompson and Marsden9 and FitzGerald and 
Jankovic10 suggested that the parkinsonism in pa­
tients showing deep white matter lesions on MRI 
or CT might be due to subcortical ischem ia.9,10 
However, in a previous study48 with proton mag­
netic resonance spectroscopy in SVP patients, we 
could not detect metabolic signs of ischemia (in­
creased lactate) in the deep white matter or in the 
striatum. Meguro et al49 reported impaired circula­
tion in brains with severe SCLs, although oxygen 
metabolism was not measurably affected. Vascular 
parkinsonism is probably due to multiple acute is­
chemic microinfarcts resulting in neuronal cell loss, 
while, later on, lactate normalizes by diffusion and
active transport and mechanisms appear that com­
pensate for the decreased oxygen supply resulting 
from decreased circulation.49 The location of SCLs 
mainly in the watershed areas indeed indicates 
their ischemic nature.
In conclusion, we showed that SVP patients had 
more SCLs than patients with PD and hyperten­
sion. This suggests a causal relationship between 
SCLs and parkinsonism in our patients with SVP. 
We observed two types of vascular parkinsonism: 
one had an insidious onset and vascular lesions 
that were diffusely located in the watershed areas; 
the other had an acute onset and lesions located in 
the subcortical gray nuclei (striatum, globus pal­
lidus, thalamus). To prove the accuracy of clinical 
symptoms and SCLs in the diagnosis of vascular 
parkinsonism, postmortem examination studies of 
SVP patients are necessary.
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